Recruiting
Phase 2

Durvalumab

Sponsor:

Wake Forest University Health Sciences

Code:

NCT05696782

Conditions

Nonsmall Cell Lung Cancer Stage III

Unresectable Non-Small Cell Lung Carcinoma

Nonsmall Cell Lung Cancer, Stage II

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Durvalumab

the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30)

COPD Assessment Test (CAT)

Modified Medical Research Council (mMRC) dyspnea scale

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Wake Forest University Health Sciences on 2025-04-23.